Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...

Sage Therapeutics (NASDAQ:SAGE) is reportedly suing Biogen (NASDAQ:BIIB) over enforcement of a standstill agreement in the ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...

Humana Inc. fell short of pleading standards in its racketeering lawsuit against Biogen Inc. over its allegedly fraudulent ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Shares of Biogen Inc. BIIB shed 1.44% to $141.00 Wednesday, on what proved to be an all-around positive trading session for ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

Biogen is looking to augment growth by hunting for biotechs with drugs in mid- and late-stage clinical development.

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

BTIG analyst Thomas Shrader has maintained their neutral stance on BIIB stock, giving a Hold rating on January 14.Stay Ahead of the ...